AU2019271189A1 - Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders - Google Patents

Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders Download PDF

Info

Publication number
AU2019271189A1
AU2019271189A1 AU2019271189A AU2019271189A AU2019271189A1 AU 2019271189 A1 AU2019271189 A1 AU 2019271189A1 AU 2019271189 A AU2019271189 A AU 2019271189A AU 2019271189 A AU2019271189 A AU 2019271189A AU 2019271189 A1 AU2019271189 A1 AU 2019271189A1
Authority
AU
Australia
Prior art keywords
cyclic
cpg
disease
proline
glycyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019271189A
Other languages
English (en)
Inventor
Lloyd Hung Loi TRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2019271189A1 publication Critical patent/AU2019271189A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019271189A 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders Abandoned AU2019271189A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862671485P 2018-05-15 2018-05-15
US201862671466P 2018-05-15 2018-05-15
US62/671,466 2018-05-15
US62/671,485 2018-05-15
US201862674855P 2018-05-22 2018-05-22
US62/674,855 2018-05-22
PCT/US2019/032403 WO2019222339A1 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Publications (1)

Publication Number Publication Date
AU2019271189A1 true AU2019271189A1 (en) 2021-01-07

Family

ID=68541027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019271189A Abandoned AU2019271189A1 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Country Status (9)

Country Link
US (3) US11090303B2 (https=)
EP (1) EP3843768A4 (https=)
JP (2) JP7699378B2 (https=)
CN (1) CN112423774A (https=)
AU (1) AU2019271189A1 (https=)
BR (1) BR112020023252A2 (https=)
GB (1) GB202015788D0 (https=)
MA (1) MA53500A (https=)
WO (1) WO2019222339A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398792A1 (en) * 2018-05-15 2024-12-05 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
EP3843768A4 (en) * 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
WO2022051631A1 (en) * 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
TW202245773A (zh) * 2021-02-12 2022-12-01 紐西蘭商紐藍製藥公司 普威二氏症候群之治療
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
KR20260049797A (ko) * 2023-07-12 2026-04-14 로이드 트란 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis
WO2025160184A1 (en) * 2024-01-23 2025-07-31 Lloyd Tran Methods for the prophylaxis and treatment of obesity and related conditions and disorders
WO2025179250A1 (en) * 2024-02-25 2025-08-28 Lloyd Tran Methods for the prophylaxis and treatment of autism related disorders
WO2025198995A1 (en) * 2024-03-18 2025-09-25 Lloyd Tran Methods for the prophylaxis and treatment of stroke related disorders
CN119770491B (zh) * 2024-12-20 2025-10-17 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670563B2 (ja) 1988-10-12 1997-10-29 富士通株式会社 半導体装置の製造方法
JP2757960B2 (ja) 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5942422A (en) 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
PT1064256E (pt) 1998-03-17 2004-10-29 Pfizer Prod Inc Biciclo[2.2.1] heptanos e compostos relacionados
US6258582B1 (en) 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
AU781044B2 (en) 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6689904B2 (en) 2001-06-29 2004-02-10 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
CA2466701C (en) * 2001-11-13 2013-11-12 Loi Tran Neuroprotective use of cyclic prolyl glycine
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US20050209142A1 (en) * 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
JP4842817B2 (ja) * 2003-09-03 2011-12-21 ニューレン ファーマシューティカルズ リミテッド 神経保護二環式化合物およびその使用方法
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
JP2021514303A (ja) * 2018-02-19 2021-06-10 ザ マテリアル ワークス，リミテッド 金属薄板デスケーラのための幅及び速度コントロールならびにそれを使用する方法
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS

Also Published As

Publication number Publication date
JP7699378B2 (ja) 2025-06-27
WO2019222339A1 (en) 2019-11-21
EP3843768A4 (en) 2022-11-23
US12070458B2 (en) 2024-08-27
BR112020023252A2 (pt) 2021-02-23
JP2021524864A (ja) 2021-09-16
EP3843768A1 (en) 2021-07-07
GB202015788D0 (en) 2020-11-18
CN112423774A (zh) 2021-02-26
US20200054629A1 (en) 2020-02-20
US11090303B2 (en) 2021-08-17
MA53500A (fr) 2021-08-18
US20220000866A1 (en) 2022-01-06
US20230381175A1 (en) 2023-11-30
JP2025084741A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
US12070458B2 (en) Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
JP4861177B2 (ja) 神経系の障害の処置
US20070244039A1 (en) Therapeutic agent composition and method of use
US20220160820A1 (en) Modulators of complement activity
US20150306171A1 (en) Therapeutic agent composition and method of use
US9327011B2 (en) Neurotrophic peptides for the treatment of tauopathies
CN116390723A (zh) 用于将生物素递送至线粒体的方法和组合物
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
CA2466701C (en) Neuroprotective use of cyclic prolyl glycine
US20230073781A1 (en) Systemic administration of peptides for the treatment of spinal cord injury and/or for remyelination
CN106459016B (zh) 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药
US11931403B2 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用
US8138304B2 (en) Neural regeneration peptides and formulations thereof
CN121816183A (zh) 治疗轻度认知障碍的治疗剂组合物以及联合疗法的应用方法
WO2022095057A1 (zh) 一种医药组合物及其医药用途
EP4190347A1 (en) Sco-spondin-derived polypeptides for treating biological barriers dysfunction
WO2025179250A1 (en) Methods for the prophylaxis and treatment of autism related disorders
CA2619721A1 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
CN116832025A (zh) 维拉帕米在制备预防、减轻或延缓椎间盘退变产品中的用途
Marcelli A novel selective cell-permeable peptide disrupts presynaptic JNK2-STX1a interaction, providing neuroprotection and preventing glutamate-mediated excitotoxicity
US20100317578A1 (en) Method of protecting against stroke through the use of a delta opioid peptide

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period